Evicenter
MarkdownMedical informationP&T meetings
Emcitate (tiratricol)

MCT8 deficiency

Last updated
81 sources

Section 3 of 6

Product information and disease description

217 evidence topics · 62 sources

Product description

Phase of product development

Summary: development and regulatory status as of November 2026

The FDA approved tiratricol (Emcitate) tablets for oral suspension on 28 September 2026 for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency (Allan-Herndon-Dudley syndrome), with a limitation of use stating that it is not recommended for the treatment of primary hypothyroidism. The approval was granted to Egetis Therapeutics US Inc., and it is the first FDA-approved treatment for MCT8 deficiency. Egetis completed a rolling NDA submission on 29 January 2026, and on 27 March 2026 announced that the FDA had accepted the application with priority review and a PDUFA target action date of 28 September 2026. Tiratricol received orphan drug designation in January 2019, rare pediatric disease designation in November 2020, fast track designation in 2021, and breakthrough therapy designation in 2025, and the FDA granted Egetis a rare pediatric disease priority review voucher in connection with the approval. The prescribing information states that efficacy was evaluated in two studies (NCT05579327 and NCT02060474); Egetis states that the approval was also supported by Triac Trial II, the EMC Cohort Study, the EMC Survival Study, and the U.S. Expanded Access Program. At approval, Egetis expected commercial availability in the United States eight to ten weeks after approval, and on 27 October 2026 it announced U.S. commercial availability. In the European Union, tiratricol was authorised on 12 February 2025 as a hybrid medicine whose reference product is Téatrois, a 0.35 mg tablet authorised in France in 1974, and it was launched in Germany on 1 May 2025. A U.S. composition patent was granted on 5 May 2026, and Egetis expects it to expire in 2045. In Japan, the licensee Fujimoto Pharmaceuticals expects to submit an NDA at the beginning of 2027.

Product information

Generic, brand name and therapeutic class of product
Generic name
FieldQuoted record
Name of medicine“Emcitate”
Active substance“tiratricol”
International non-proprietary name (INN) or common name“tiratricol”
Dosage forms and strengths
Material safety data sheet

No evidence found.

Average sales price and wholesale acquisition cost
Summary: estimated monthly and annual cost
  • Price basis: $74,000 per pack, the price stated by an executive of ANI Pharmaceuticals, which has offered to acquire Egetis Therapeutics, at the Jefferies Global Healthcare Conference on 17 November 2026. No wholesale acquisition cost published by Egetis or in a state price transparency filing was found, so this is a rounded, press-reported list price. The pack is the carton of 60 tablets of 350 mcg (NDC 87216-0100-1), so $74,000 ÷ 60 = $1,233.33 per tablet. Trade press reported a list price of around $950,000 per year at the October 2026 launch.
  • Dosing basis: dosage is individualized by body weight, total T3 concentration, and signs of thyrotoxicosis; the mean maintenance dose in Study 2 of the prescribing information was 741 mcg per day. Tablets carry a functional score and can be split into equal halves, with the unused half stored for later use, so cost is computed per tablet used.
  • Base case: 741 mcg per day. 741 mcg ÷ 350 mcg = 2.117 tablets per day × $1,233.33 = $2,611.14 per day × 365 days = $953,067 per year; ÷ 12 = $79,422 per month.
  • Range: $225,083 per year ($18,757 per month) at 175 mcg per day (half a tablet) to $3,858,571 per year ($321,548 per month) at 3,000 mcg per day: 3,000 mcg ÷ 350 mcg = 8.571 tablets per day × $1,233.33 = $10,571.43 per day × 365 days = $3,858,571 per year; ÷ 12 = $321,548 per month. The 350 mcg per day starting dose for patients weighing more than 10 kg costs $450,167 per year ($37,514 per month).
  • Rationale for the range: the lower bound is the starting dose for patients weighing 10 kg or less. The prescribing information reports the Study 1 and Study 2 populations by age and the Study 2 maintenance dose as a mean, and the Study 2 publication and its appendix report doses per kilogram of body weight; no cited source reports the highest body weight or the highest daily dose administered in either study. The upper bound is therefore the maximum recommended dosage for the heaviest weight band the label names, 50 mcg/kg/day for patients weighing 60 kg and above, at the band's threshold of 60 kg. Doses above the upper bound are permitted at two points in the weight scale: the 40 kg to less than 60 kg band allows 60 mcg/kg/day, which approaches 3,600 mcg per day ($4,630,286 per year) just below 60 kg, and the 50 mcg/kg/day maximum reaches 3,600 mcg per day at 72 kg. Titration in 175 mcg or 350 mcg steps about every two weeks to a total T3 target, and dosage reductions of the same size for new or worsening thyrotoxicosis, set each patient's dose, and the first year costs less than later years while the dose is titrated upward. Price is per tablet, so cost is proportional to dose.
  • Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.
Product pricing, Germany: pharmacy sales price and statutory rebates
Packaging sizeCosts (pharmacy sales price)Rebate Section 130 SGB VRebate Section 130a SGB VCosts after deduction of statutory rebatesPrice list revision
“60 TOS”“€ 15,415.68”“€ 1.77”“€ 877.10”“€ 14,536.81”“15 August 2025”
American hospital formulary service (AHFS), or other drug classification
ATC classification
FieldQuoted record
Anatomical therapeutic chemical (ATC) code“H03AA04”
Pharmacotherapeutic group“Thyroid therapy”
Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Healthy-volunteer bioequivalence, food-effect, and dose-proportionality study

“This study investigates the pharmacokinetics (PK) of tiratricol.” (opens the source at this quote in a new tab)

“This novel Phase 1, randomized, five-period cross-over study was a hybrid combination of a two-period cross-over and a three-period balanced incomplete block design in healthy adult male subjects (n = 30) with a washout of ≥3 days between periods.” (opens the source at this quote in a new tab)

“Bioequivalence was established between 350μg tiratricol oblong and 350μg tiratricol round tablets in terms of AUC and Cmax with a serum half-life of approximately 13h for both administrations.” (opens the source at this quote in a new tab)

“Overall exposure (AUC) was comparable between the fasted and fed state.” (opens the source at this quote in a new tab)

“Absorption was rapid in the fasted state (median Tmax 0.5 hr) but slower in the fed state (median Tmax approximately 1.5 hr), with Cmax 67–70% lower.” (opens the source at this quote in a new tab)

“Cmax following treatment with the 175μg, 350μg, and 1050μg oblong tablet doses increased proportionally with increasing dose, whereas AUC increased in a slightly greater than proportional manner with increasing dose.” (opens the source at this quote in a new tab)

“Tiratricol was well tolerated in all doses and fasting states, with no serious adverse events recorded.” (opens the source at this quote in a new tab)

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Interference with thyroid hormone laboratory measurements
Special populations
Pediatric use
Drug/Drug, drug/disease interactions
Effects of other drugs on tiratricol
Drugs that may affect tiratricol: European summary of product characteristics
Drug or drug classStatement in the summary of product characteristics
Antacids, charcoal, calcium, cationic resins, iron, and sucralfate“Antacids, charcoal, calcium, cationic resins (e.g. cholestyramine), iron, sucralphate, and other gastrointestinal agents may interfere with the gastrointestinal absorption of tiratricol. These treatments should be taken before or after tiratricol (more than 2 hours before or after if possible). In the case of cholestyramine, tiratricol should be taken 1 hour before or 4 hours after the resin dose.”
Proton pump inhibitors“Co-administration with PPIs may cause a decrease in the absorption of the thyroid hormones, due to the increase of the intragastric pH caused by PPIs such as omeprazole, esomeprazole, pantoprazole, rabeprazole and lansoprazole. Serum concentrations of T3 should be monitored and dose adjustment of tiratricol considered when initiating, changing or discontinuing PPI treatment.”
Sevelamer“Sevelamer may decrease the concentration of thyroid hormones and result in reduced efficacy of tiratricol. Sevelamer should be taken more than 2 hours before or after administration of tiratricol.”
Enzyme inducers, including antiepileptics“Medicinal products that can induce the enzyme system in the liver, such as barbiturates, phenytoin carbamazepine, rifabutin, rifampicin or products containing St. John’s wort (Hypericum perforatum) may increase the hepatic clearance of tiratricol.”
Antimalarials“Concomitant use of tiratricol and antimalarial medicinal products (chloroquine, proguanil) may cause clinical hypothyroidism.”
Non-contraceptive oestrogens“Non-contraceptive oestrogen and oestrogen containing products (including hormone replacement therapy) may increase the requirement of tiratricol treatment dose.”
Orlistat“Orlistat may decrease tiratricol absorption which may result in hypothyroidism (changes in thyroid function should be monitored).”
Effects of tiratricol on other drugs
Dosing and administration
Dosage
Starting dosage, titration increment, and dosage reduction by body weight
Body weightRecommended starting dosageTitration incrementDosage reduction for new or worsening thyrotoxicosisDiscontinuation taper
10 kg or less“175 mcg/day”“175 mcg/day.”“175 mcg”“reduce EMCITATE by 175 mcg/day once every two weeks.”
Greater than 10 kg“350 mcg/day”“350 mcg/day.”“350 mcg”“reduce EMCITATE by 350 mcg/day once every two weeks.”
Maximum recommended dosage by body weight
Body weightMaximum recommended dosage
Less than 10 kg“100 mcg/kg/day”
10 kg to less than 40 kg“80 mcg/kg/day”
40 kg to less than 60 kg“60 mcg/kg/day”
60 kg and above“50 mcg/kg/day”
Starting dose by body weight: published management recommendations
Body weightStarting dose
Less than 10 kg“175 µg once daily”
10 kg or greater“350 µg once daily”
Maximum daily dose by body weight: published management recommendations
Body weightMaximum daily dose
Less than 10 kg“100 µg/kg/day”
10–40 kg“80 µg/kg/day”
40–60 kg“60 µg/kg/day”
More than 60 kg“50 µg/kg/day”
Administration
Access and distribution
Co-prescribed/Concomitant therapies
Effect of tiratricol on quality measures

No evidence found.

Product comparison

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of MCT8 deficiency
Nationwide Japanese epidemiology: incidence
MeasureEstimate
Incidence per million births in Japan, with 95% confidence interval“2.12 (95 % CI: 0.99–3.25)”View highlighted excerpt for this quote
Prevalence of MCT8 deficiency
Nationwide Japanese epidemiology: prevalence
Natural history, survival, and mortality
Pathophysiology
Diagnosis
Guideline recommendations for diagnostic evaluation and SLC16A2 sequencing

“When considering a diagnosis of MCT8 deficiency, we recommend a full clinical assessment to determine whether the patient exhibits any recognized clinical phenotypes and a physical examination, including neurological assessment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“If MCT8 deficiency is suspected, we recommend additional investigations including (but not limited to) serum (free) T3, (free) T4, reverse T3 (rT3) and TSH concentrations (interpreting results in the context of age-specific reference intervals)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend that SLC16A2 sequencing be performed in any male patient with: the following ‘major criteria’; typical biochemical profile (TSH within normal range or mildly raised, low or low-normal (F)T4, raised (F)T3, low reverse T3, and/or elevated (F)T3/(F)T4 or T3/rT3 ratio) in combination with either global developmental delay, hypomyelination on MRI, clinical signs of movement disorder (e.g. dystonia, bradykinesia), persistent primitive reflexes, or a positive family history for MCT8 deficiency” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Definitive diagnosis of MCT8 deficiency requires identification of a known pathogenic mutation, either by reliable in silico prediction and/or functional studies of novel variants in transfected cells or patient-derived cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Clinical presentation - signs and symptoms
Developmental milestones: Japanese nationwide survey
FindingParticipants with finding (evaluable denominator in label)
Completion of head control, n = 28“7 (25 %)”View highlighted excerpt for this quote
Able to keep sitting, n = 28“0 (0 %)”View highlighted excerpt for this quote
Able to speak a word, n = 27“0 (0 %)”View highlighted excerpt for this quote
Abnormal sleep rhythm, n = 27“9 (33 %)”View highlighted excerpt for this quote
Feeding difficulty, n = 26“4 (15 %)”View highlighted excerpt for this quote
Cardiovascular and nutritional manifestations: international natural-history cohort
ManifestationAffected participants and evaluable denominator
Elevated systolic blood pressure above the 90th percentile“25 (53%) of 47”
Premature atrial contractions“34 (76%) of 45”
Resting tachycardia“20 (31%) of 64”
Underweight“59 (71%) of 83”
Long-term morbidity
Burden of MCT8 deficiency
Humanistic burden and health-related quality of life
Economic burden and healthcare resource utilization
Economic impact of MCT8 deficiency on families

No evidence found.

Economic impact of diagnostic testing

Approaches to treatment

Current treatment options and standard of care
Thyroid hormone analogues
Combined levothyroxine and propylthiouracil
Nutritional support and enteral feeding
Symptom-directed neurological pharmacotherapy
Rehabilitation and multidisciplinary supportive care
Limitations of current therapies
Summary

Available therapies address peripheral thyrotoxicosis and individual symptoms; none has been shown to restore neurodevelopment. The 2024 European Thyroid Association guideline states that no available treatment regimen has rescued the neurocognitive phenotype and that the effectiveness of supportive neurological and gastrointestinal interventions has not been evaluated in MCT8 deficiency. Levothyroxine monotherapy did not improve neurodevelopment and in some cases aggravated peripheral thyrotoxicosis. In Triac Trial II, in participants younger than 30 months at enrollment, tiratricol reduced total serum T3 but did not meet its co-primary GMFM-88 and BSID-III gross motor endpoints compared with natural history scores from Triac Trial I. In a case series of 12 participants receiving combined levothyroxine and propylthiouracil, serum thyroid hormone concentrations normalized, but metabolic and physical parameters did not differ significantly between baseline and the last encounter, and the guideline advises weighing the risk of severe propylthiouracil adverse effects. Supportive care is inconsistently delivered: in an international parent registry, 11 of 36 participants received professional dietary advice and 2 of 16 participants with feeding problems had a feeding tube.

Place in treatment, anticipated use, and care setting
Summary

Tiratricol is approved in the United States (September 2026) for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency and in the EU (February 2025) for peripheral thyrotoxicosis in MCT8 deficiency from birth; it is the first FDA-approved treatment for the disease. The 2024 European Thyroid Association guideline recommends TRIAC (strong recommendation) or DITPA (weak recommendation) with long-term therapy, and suggests combined levothyroxine and propylthiouracil only when thyroid hormone analogues are unavailable. The label advises against combining tiratricol with other thyroid medications such as levothyroxine and propylthiouracil. Dosing is individualized by body weight, total T3 measured by LC-MS/MS, and signs and symptoms of thyrotoxicosis, and the suspension can be given by mouth or through a feeding tube. A 2026 monitoring guideline notes that TRIAC costs substantially more than conventional thyroid hormone preparations and that treatment may be deferred in individual cases, such as patients without biochemical or cardiovascular evidence of thyrotoxicosis. Tiratricol does not replace supportive management of feeding difficulties, developmental disability, spasticity, or movement disorders. In the United States it is dispensed through PANTHERx Rare with the Egetis RareLink support program; before approval, the U.S. Expanded Access Program included 17 hospitals and approximately 60 treated individuals.

Heterogeneity of treatment effect
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA
FDA post-marketing obligations

No evidence found.

Ongoing post-approval monitoring
Expected outcomes of therapy